This event has passed

January 28 - Virtual Workshops
Morning Session
10:00-11:00
Biologics: Protein Alignments, Modeling and Docking
Protein Alignments and Superposition / Loop and Linker Modeling / Homology Modeling / Protein- Protein Docking
Sarah Witzke, Applications Scientist, Chemical Computing Group (UK)
11:00-11:15
Morning Break
11:15-12:15
Antibody Modeling and Protein Engineering
Protein Engineering / Protein Properties / Developability / Hot Spot Analysis / Antibody Modeling / Humanization / Molecular Surfaces
Freya (Klepsch) Trasischker, Senior Applications Scientist, Chemical Computing Group (AT)
January 28 - Scientific Presentations
Afternoon Session
13:30-13:35
Opening Remarks
CHAIR: Fabrizio Comper
13:35-14:05
Developability Optimization of Antibodies 
Anette Henriksen, Principal Scientist, Novo Nordisk A/S (DK)
14:05-14:35
Platformization of Multi-Specific Protein Engineering: Learning from High-Throughput Screening Data 
Norbert Furtmann, Section Head Data Science & Computational Design, Biologics Research, Sanofi Deutschland GmbH (DE)
14:35-15:05
mAb Biobetter: Immunogenicity Risk Reduction by Rational Design 
Sébastien Irigaray, Senior Scientist, Novartis (CH)
15:05-15:35
Towards More Accurate Property Prediction and Developability Profiling for Biologics 
David Thompson, Senior Applications Scientist, Chemical Computing Group (US)
15:35-15:45
Break
CHAIR: Giuseppe Licari
15:45-16:15
The Cellular Membrane as a Major Platform for Drug Interaction with the Cell 
Emad Tajkhorshid, Director of NIH Biotechnology Center for Macromolecular Modeling and Bioinformatics, Beckman Institute, University of Illinois (US)
16:15-16:45
Computational Design of Microbial Transglutaminase 
Shira Warszawski, Senior Scientist, Merck KGaA (IL)
16:45-17:15
Protein Engineering in Gene Therapy: The Case of Haemophilia A 
Fabrizio Comper, Scientific Director, Freeline Therapeutics (UK)
17:15-17:45
Intrinsic Physicochemical Properties of Currently Marketed Biologic Medicines 
Sandeep Kumar, Senior Research Fellow (Biotherapeutics) and Group Leader, Boehringer Ingelheim (US)
17:45-17:50
Closing Remarks